The cannabis industry is constantly evolving, with new products and derivatives of the plant’s over 100 cannabinoids emerging on the market. Recently, delta-8 and delta-10 THC have gained popularity among cannabis enthusiasts and patients alike for their unique chemical structures and potential medical applications. While delta-9 THC has been the most extensively studied psychoactive cannabinoid, delta-8 and delta-10 THC offer new possibilities for researchers and consumers alike.
Despite their potential benefits, these new compounds also come with controversy surrounding their legality and lack of clinical studies. However, researchers like Prakash Nagarkatti and Mitzi Nagarkatti are actively exploring the effects of marijuana cannabinoids on inflammation and cancer, suggesting that these compounds may have a place in the medical field.
In this article, we will delve into the world of delta-8 and delta-10 THC, exploring their differences from delta-9 THC, their potential medical applications, and the legal challenges surrounding their use.
Cannabinoids and Cannabis Varieties
Cannabis sativa contains over 100 cannabinoids, with delta-9 THC being the most extensively researched psychoactive cannabinoid.
Marijuana and hemp are two different varieties of the cannabis plant, with their differences determined by the amount of delta-9 THC present.
Marijuana typically contains 10-30% delta-9 THC, while hemp contains 5-15% CBD.
Cannabis strains can have different cannabinoid profiles, which can affect the body in various ways.
For example, some cannabinoids may have anti-inflammatory properties, while others may have psychoactive effects.
Delta-8 and delta-10 THC are two new cannabis-derived products that have gained popularity in recent years.
The chemical difference between these cannabinoids and delta-9 THC is the position of a double bond on their carbon atom chains.
While delta-9 THC is believed to be the primary cannabinoid responsible for marijuana’s psychoactive effects, delta-8 THC is less psychoactive and may be preferable for treating inflammation.
However, there are no published clinical studies on the medical applications of delta-8 THC, and the sale of delta-8 THC is controversial due to its legal status as a Schedule I controlled substance.
Delta-10 THC is not well-studied, and its medicinal properties are unknown.
Delta-8 THC vs Delta-9 THC
The most well-known psychoactive cannabinoid, delta-9 THC, has been found to be present in marijuana at levels of 10-30%, while hemp contains less than 0.3%, according to federal regulations.
Delta-8 THC, on the other hand, is a new cannabis-derived product that has recently gained popularity due to its purported medicinal properties, including its potential to alleviate inflammation. Delta-8 THC is structurally similar to delta-9 THC, with the only difference being the position of a double bond on their carbon atom chains.
While delta-8 THC is less psychoactive than delta-9 THC, it is still a psychoactive substance that can produce a range of effects, including euphoria, relaxation, and increased appetite.
However, it is important to note that there are potential risks associated with the use of delta-8 THC, including impaired coordination and cognitive function, as well as potential negative effects on mental health.
More research is needed to fully understand the comparative effects and potential risks of delta-8 THC versus delta-9 THC, as well as the long-term effects of delta-8 THC use.
Medical Applications and Legal Controversy
Research on the medical applications and legal controversy surrounding delta-8 THC is ongoing. Proponents of delta-8 THC suggest it may have potential therapeutic benefits for inflammation, anxiety, and pain relief, as well as being less psychoactive than delta-9 THC. However, there are currently no published clinical studies on the medical applications of delta-8 THC, and the research that does exist is limited. More research is needed to fully understand the potential medical benefits of delta-8 THC and to determine its safety and efficacy.
In addition to the lack of research, regulatory challenges also surround the sale and use of delta-8 THC. In July 2020, the DEA issued an Interim Final Rule that classified all synthetically derived tetrahydrocannabinols as Schedule I controlled substances, including delta-8 THC. This classification has caused confusion and controversy within the cannabis industry, with some states banning the sale of delta-8 THC products and others allowing it.
It is essential to note that the legality of delta-8 THC varies depending on the state, and consumers should research their local laws before purchasing or using any cannabis-derived products.
